Skip to main content
Clinical Trials/ISRCTN98064931
ISRCTN98064931
Completed
未知

In patients with chronic plantar fasciitis, does post-injection load restriction compared to no load restriction improve recovery time and pain reduction following autologous whole-blood injection?

sak University0 sites152 target enrollmentAugust 9, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
Recovery from plantar fasciitis in adults undergoing autologous whole-blood injection with and without load restriction
Sponsor
sak University
Enrollment
152
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 9, 2024
End Date
February 2, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
sak University

Eligibility Criteria

Inclusion Criteria

  • 1\. Age Range: 20 to 65 years old
  • 2\. Diagnosis: Diagnosed with plantar fasciitis that has not responded to at least two months of conservative treatment
  • 3\. Treatment History: No prior history of autologous whole\-blood injections for plantar fasciitis
  • 4\. Consent: Willingness to provide informed consent for participation in the study
  • 5\. Mobility: Capable of using Canadian crutches if assigned to the load restriction group
  • 6\. Health Status: No significant systemic diseases or conditions affecting the foot or plantar fascia

Exclusion Criteria

  • 1\. Heavy Labor Employment: Participants who are employed in jobs involving heavy physical labor
  • 2\. Use of Immunomodulatory Drugs: Individuals who are currently using immunomodulatory medications
  • 3\. Previous Injection History: Patients with a history of previous injections for plantar fasciitis
  • 4\. Bilateral Plantar Fasciitis: Individuals diagnosed with plantar fasciitis in both feet
  • 5\. Previous Foot Surgery: Patients who have undergone foot surgery in the past
  • 6\. Local Anesthetic Sensitivity: Individuals with known sensitivity or adverse reactions to local anesthetics
  • 7\. Rheumatological Diseases: Participants with diagnosed rheumatological conditions
  • 8\. Autoimmune/Neuropathic Diseases: Individuals with autoimmune or neuropathic disorders

Outcomes

Primary Outcomes

Not specified

Similar Trials